Goldman Sachs
NVIV

Goldman Sachs’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Goldman Sachs’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Hold
0
– -$8K – 7170
2016
Q4 		– Hold
0
– – – 6787
2016
Q3 		– Hold
0
– – – 6832
2016
Q2 		– Sell
-13
Closed -$1.75M – 7419
2016
Q1 		$1.75M Hold
13
– – ﹤0.01% 3611
2015
Q4 		$1.8M Buy
+13
New +$1.93M ﹤0.01% 3731

Goldman Sachs's NVIV Position: Q2 2024 in Review

Goldman Sachs sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2024, closing a stake of 23,741 shares — an estimated $5.22K sold.

Goldman Sachs first reported a position in NVIV in Q2 2015 and held it in 13 quarters. The position peaked at $2.44M in Q1 2016. 0 funds tracked by Wall St. Rank hold NVIV as of Q2 2024.

  • Goldman Sachs reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2024 after selling out during the quarter.
  • Goldman Sachs sold 23,741 InVivo Therapeutics Holdings Corp shares in Q2 2024, an estimated $5.22K.
  • Goldman Sachs first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 13 quarters.
  • Goldman Sachs's InVivo Therapeutics Holdings Corp position peaked at $2.44M in Q1 2016.
  • 0 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.